1-10 of 10
Paul Cheng
Close
Sort by
Journal Articles

Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume

Clinical Trials & Observations
Frederick L. Locke, Olalekan O. Oluwole, John Kuruvilla, Catherine Thieblemont, Franck Morschhauser, Gilles Salles, Steven P. Rowe, Saran Vardhanabhuti, Joshua Winters, Simone Filosto, Christina To, Paul Cheng, Marco Schupp, Ronald Korn, Marie José Kersten
Journal: Blood
Blood (2024) 143 (24): 2464–2473.
https://doi.org/10.1182/blood.2023021620
Published: 2024
Includes: Supplemental data
Journal Articles

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Clinical Trials & Observations
Mahmoud Elsawy, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D. Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Paul Cheng, Christina To, Marie José Kersten
Journal: Blood
Blood (2022) 140 (21): 2248–2260.
https://doi.org/10.1182/blood.2022015478
Published: 2022
Includes: Supplemental data
Journal Articles

Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7

Frederick L. Locke, Olalekan O. Oluwole, John Kuruvilla, Catherine Thieblemont, Franck Morschhauser, Gilles Salles, Steven P Rowe, Saran Vardhanabhuti, Simone Filosto, Christina To, Paul Cheng, Marco Schupp, Ronald Korn, Marie José Kersten
Journal: Blood
Blood (2022) 140 (Supplement 1): 638–640.
https://doi.org/10.1182/blood-2022-158492
Published: 2022
Journal Articles

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Frederick L. Locke, David B. Miklos, Caron Jacobson, Miguel-Angel Perales, Marie José Kersten, Olalekan O. Oluwole, Armin Ghobadi, Aaron P. Rapoport, Joseph P. McGuirk, John M. Pagel, Javier Muñoz, Umar Farooq, Tom Van Meerten, Patrick M. Reagan, Anna Sureda, Ian W. Flinn, Peter Vandenberghe, Kevin Song, Michael Dickinson, Monique C. Minnema, Peter A. Riedell, Lori A. Leslie, Sridhar Chaganti, Yin Yang, Simone Filosto, Marco Schupp, Christina To, Paul Cheng, Leo I. Gordon, Jason R. Westin
Journal: Blood
Blood (2021) 138 (Supplement 1): 2.
https://doi.org/10.1182/blood-2021-148039
Published: 2021
Journal Articles

Burden of Illness and Outcomes in the 2nd Line Treatment of Large B-Cell Lymphoma: A Real-World Comparison of Medicare Beneficiaries with and without Stem Cell Transplants

Karl M Kilgore, PhD, Anny C Wong, PhD, Julia Thornton Snider, PhD, Paul Cheng, MDPhD, Amy Schroeder, BPharm, Iman Mohammadi, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-134812
Published: 2020
Journal Articles

Lines of Therapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma and Stem Cell Transplant-Intended Treatment

Julia Thornton Snider, PhD, Paul Cheng, MDPhD, Xue Song, PhD, Donna McMorrow, David Diakun
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-134808
Published: 2020
Journal Articles

Cytotoxicity of the Recombinant Human Arginase (BCT-100) Against Acute Lymphoblastic Leukaemia (ALL)

Francis J Mussai, MA(Oxon), BM, BCh, DPhil, Sarah Booth, BSc, Ashley Vardon, MD, Margaret Ng, MB ChB MDCUHK), Paul Cheng, MDPhD, Carmela De Santo, PhD
Journal: Blood
Blood (2015) 126 (23): 4916.
https://doi.org/10.1182/blood.V126.23.4916.4916
Published: 2015
Journal Articles

Utilization Patterns of Bone-Targeting Agents Among Patients with Multiple Myeloma: Analysis of Real-World Data

Yi Qian, PhD, Debajyoti Bhowmik, B.Pharm, PhD, Nandita Kachru, MS, Rohini K. Hernandez, PhD, Paul Cheng, MD PhD, Alexander Liede, BSc, MSc, PhD
Journal: Blood
Blood (2015) 126 (23): 4501.
https://doi.org/10.1182/blood.V126.23.4501.4501
Published: 2015
Journal Articles

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target

Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones, Tracey Perry, Andrew Beggs, Elena Odintsova, Justin Loke, Guy Pratt, Kin Pong U, Anthony Lo, Margaret Ng, Pamela Kearns, Paul Cheng, Carmela De Santo
Journal: Blood
Blood (2015) 125 (15): 2386–2396.
https://doi.org/10.1182/blood-2014-09-600643
Published: 2015
Includes: Supplemental data
Journal Articles

Cytotoxicity of the Recombinant Human Arginase (BCT-100) Against Acute Myeloid Leukaemia (AML)

Francis J Mussai, MA(Oxon), BM, BCh, DPhil, Sharon Egan, Joseph Higginbotham-Jones, Anthony Lo, Margaret Ng, MD, Tracey A Perry, BSc, Justin Loke, Andrew D Beggs, BSC(Hons), MBBS, PhD, Guy Pratt, Pamela R Kearns, MBChB, PhD FRCPCH, Paul Cheng, MD PhD, Carmela DeSanto, PhD
Journal: Blood
Blood (2014) 124 (21): 2317.
https://doi.org/10.1182/blood.V124.21.2317.2317
Published: 2014